Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges

(2019) Alexander A. Vinogradov et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy

(2019) Yao Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis of Tofisopam by Way of Photoinduced CO 2 Fixation

(2019) Yusuke Masuda et al.   Chemistry-An Asian Journal

Recent developments of chalcones as potential antibacterial agents in medicinal chemistry

(2019) Wenjia Dan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201

(2018) Sébastien Jeay et al.   CANCER RESEARCH

The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy

(2018) Guochao Liao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

(2018) Vincent A. de Weger et al.   BRITISH JOURNAL OF CANCER

Design, synthesis and cytotoxic activity of certain novel chalcone analogous compounds

(2017) S. El-Meligie et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 labeled with carbon-13 and carbon-14

(2017) Bachir Latli et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

The Current State of Peptide Drug Discovery: Back to the Future?

(2017) Antoine Henninot et al.   JOURNAL OF MEDICINAL CHEMISTRY

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment

(2016) Loredana Urso et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Stereodivergent Synthesis of Chromanones and Flavanones via Intramolecular Benzoin Reaction

(2016) Genfa Wen et al.   ORGANIC LETTERS

Clinical Overview of MDM2/X-Targeted Therapies

(2016) Andrew Burgess et al.   Frontiers in Oncology

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

(2015) M. Andreeff et al.   CLINICAL CANCER RESEARCH

In vitro and in vivo anti-glioma activity of a chalcone-quinoxaline hybrid

(2015) Gecioni Loch-Neckel et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

(2015) Philipp Holzer et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

(2014) Daqing Sun et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

(2014) Yujun Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53–MDM2 Protein–Protein Interaction

(2012) Chunlin Zhuang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

(2010) Grzegorz M. Popowicz et al.   CELL CYCLE